heart failure

Boehringer, Yale trial digital tech in heart failure
Boehringer, Yale trial digital tech in heart failure
Pharmaforum
Boehringer Ingelheim
Yale
digital therapeutics
digital health
heart failure
Flag link:
ESC: Merck's Steglatro shows limited promise with heart failure hospitalization data
ESC: Merck's Steglatro shows limited promise with heart failure hospitalization data
Fierce Pharma
Merck
Steglatro
ESC
heart failure
Flag link:
ESC: Novartis' Entresto racks up a heart failure study win—but it's a mixed one
ESC: Novartis' Entresto racks up a heart failure study win—but it's a mixed one
Fierce Pharma
Novartis
Entresto
ESC
heart failure
Flag link:
ESC 2020 – Jardiance joins Farxiga in showing heart failure benefit
ESC 2020 – Jardiance joins Farxiga in showing heart failure benefit
EP Vantage
ESC
Eli Lilly
Boehringer Ingelheim
Farxiga
Jardiance
heart failure
AstraZeneca
Flag link:
Boehringer and Lilly’s Jardiance Hits Mark in Decreasing Risk of Death in Heart Failure
Boehringer and Lilly’s Jardiance Hits Mark in Decreasing Risk of Death in Heart Failure
BioSpace
Boehringer Ingelheim
Eli Lilly
Jardiance
heart failure
diabetes
clinical trials
Flag link:
Novartis' Entresto gains steam with cardiologists despite stinging heart failure trial flop
Novartis' Entresto gains steam with cardiologists despite stinging heart failure trial flop
Fierce Pharma
Novartis
Entresto
heart failure
cardiologists
Flag link:
FDA Grants Breakthrough Designation for Heart Failure Device
FDA Grants Breakthrough Designation for Heart Failure Device
Medical Devices and Diagnostics Industry
VisCardia
VisOne
heart failure
devices
FDA
Flag link:
ACC: Bayer and Merck’s vericiguat leads off virtual meeting with positive phase 3 heart failure data
ACC: Bayer and Merck’s vericiguat leads off virtual meeting with positive phase 3 heart failure data
Fierce Biotech
ACC
Merck
Bayer
heart failure
vericiguat
clinical trials
Flag link:
Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
EP Vantage
Bayer
Merck
vericiguat
heart failure
AKR-001
Akero Therapeutics
clinical trials
NASH
Flag link:
AstraZeneca kicks off 2020 with double win in US and China
AstraZeneca kicks off 2020 with double win in US and China
Pharmaforum
AstraZeneca
FDA
Farxiga
heart failure
China
Lokelma
hyperkalemia
Flag link:
Eli Lilly, Boehringer's Jardiance flops heart failure trial, falling behind AZ's Farxiga
Eli Lilly, Boehringer's Jardiance flops heart failure trial, falling behind AZ's Farxiga
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
Farxiga
diabetes
AstraZeneca
heart failure
Flag link:
Hitting the road: AstraZeneca launches tour to highlight link between diabetes and heart failure
Hitting the road: AstraZeneca launches tour to highlight link between diabetes and heart failure
Fierce Pharma
AstraZeneca
diabetes
type 2 diabetes
heart failure
Flag link:
AstraZeneca, Novoheart to Co-Develop New Heart Model
AstraZeneca, Novoheart to Co-Develop New Heart Model
Xconomy
AstraZeneca
Novoheart
heart-in-a-jar
heart failure
Flag link:
AHA: Lilly, Boehringer's Jardiance cuts CV hospitalizations over rival diabetes meds
AHA: Lilly, Boehringer's Jardiance cuts CV hospitalizations over rival diabetes meds
Fierce Pharma
diabetes
AHA
heart failure
Eli Lilly
Boehringer Ingelheim
Jardiance
clinical trials
Flag link:
Janssen taps wearable tech in Invokana heart failure trial
Janssen taps wearable tech in Invokana heart failure trial
Pharmaforum
JNJ
Janssen
Invokana
heart failure
wearables
real world evidence
clinial trials
Flag link:
Boehringer, Eli Lilly begin sixth phase III study for Jardiance in heart failure
Boehringer, Eli Lilly begin sixth phase III study for Jardiance in heart failure
Pharmaceutical Business Review
Boehringer Ingelheim
Eli Lilly
Jardiance
heart failure
Flag link:
Gene therapy to fend off aging? Buzzy Harvard startup Rejuvenate Bio says it works in mice
Gene therapy to fend off aging? Buzzy Harvard startup Rejuvenate Bio says it works in mice
Fierce Biotech
gene therapy
age-related disease
type 2 diabetes
obesity
heart failure
kidney failure
Rejuvenate Bio
Flag link:
Highlights: 2019 Cardiometabolic Health Congress, Chicago IL
Highlights: 2019 Cardiometabolic Health Congress, Chicago IL
CP Wire
cardiometabolic health
GLP-1 agonist
diabetes
lipids
hypertension
chronic kidney disease
heart failure
obesity
Flag link:
Highlights: 2019 Cardiometabolic Health Congress, Chicago IL
cardiometabolic health
GLP-1 agonist
diabetes
lipids
hypertension
chronic kidney disease
heart failure
obesity
Flag link:
AstraZeneca's Farxiga scores FDA nod to cut risk of hospitalization for heart failure in diabetics
AstraZeneca's Farxiga scores FDA nod to cut risk of hospitalization for heart failure in diabetics
Endpoints
AstraZeneca
Farxiga
type 1 diabetes
heart failure
Flag link:

Pages